Evercore ISI downgraded Theravance Biopharma to In Line from Outperform with an $8 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TBPH: